| Target Molecule | Eptifibatide |
| Synonyms | Integrilin, Integrelin, Intrifiban; Mpa-Har-Gly-Asp-Trp-Pro-Cys-NH₂ cyclic (1→6)-disulfide |
| CAS Number | 188627-80-7 (anhydrous form 148031-34-9) |
| Sequence (3-Letter) | Mpa-Har-Gly-Asp-Trp-Pro-Cys-NH₂ (cyclic (1→6)-disulfide; Mpa = 3-mercaptopropionyl, Har = homoarginine) |
| Sequence (1-Letter) | Mpa-hArg-G-D-W-P-C-NH₂ (cyclic Mpa–Cys disulfide) |
| Molecular Formula | C₃₅H₄₉N₁₁O₉S₂ |
| Molecular Weight | 831.96 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Directed Disulfide Cyclization |
| Modification Options | Intramolecular disulfide bridging, homoarginine incorporation, stable isotope labeling (13C, 15N), C-terminal amidation |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Eptifibatide (CAS 188627-80-7) is a synthetic cyclic heptapeptide functioning as a platelet glycoprotein IIb/IIIa receptor antagonist. We target this sequence to supply high-purity reference materials, analytical standards, and raw materials for cardiovascular and antiplatelet research.
We utilize optimized solid-phase peptide synthesis (SPPS) and directed oxidative folding techniques. Our platform ensures precise incorporation of homoarginine and mercaptopropionyl residues alongside exact ring closure via the Mpa–Cys disulfide bond, preventing linear precursors and polymeric aggregation.
Yes. We provide specialized peptide modification services for GPIIb/IIIa antagonists. Options include site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), fluorescent or biotin tagging, and the synthesis of related peptide impurities.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (such as TFA removal to acetate) to ensure strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Eptifibatide (CAS 188627-80-7), historically known as Integrilin, is a synthetic cyclic heptapeptide defined by the sequence Mpa-Har-Gly-Asp-Trp-Pro-Cys-NH2 with an intramolecular disulfide bridge. Synpeptide provides comprehensive custom synthesis solutions for this molecule. Constructing this constrained cyclic sequence demonstrates our advanced technical capabilities in controlled oxidative folding, non-standard amino acid assembly, and CDMO manufacturing.
Assembling the 7-residue cyclic sequence requires high-fidelity sequence elongation followed by meticulous intramolecular cyclization between mercaptopropionyl and cysteine residues. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) protocols, sequence-specific resin selection, and directed oxidative folding techniques to ensure exact stereochemical fidelity and high-yield ring closure.
Eptifibatide incorporates specialized residues such as homoarginine (Har) and 3-mercaptopropionyl (Mpa). Through our peptide modification services, we routinely synthesize related sequences, provide stable isotope labeling (13C, 15N) for quantitative bioanalysis, and synthesize specific linear precursors or structural variants as critical impurity reference standards.
Transitioning a cyclic heptapeptide from laboratory screening to commercial production requires robust downstream processing. The high-dilution conditions required to prevent intermolecular oligomerization during cyclization demand specialized engineering. We execute large-scale peptide synthesis for Eptifibatide using continuous-flow oxidation systems and high-capacity preparative HPLC purification, scaling seamlessly from milligram research quantities to kilogram commercial lots with verified batch-to-batch consistency.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our technical teams assist pharmaceutical developers through process optimization, rigorous stability assessments, analytical method validation, and complete regulatory documentation. We provide the precise data and scalable manufacturing required to advance complex cyclic peptide APIs through the development lifecycle.
